Bio-Rad Signs Agreement to Acquire Certain Diagnostics Businesses of Biotest AG
HERCULES, CA -- (Marketwire) -- 10/23/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros. The terms of the agreement were not disclosed at this time. The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.
Based in Germany, Biotest develops, manufactures, and markets pharmaceutical, biotherapeutic, and diagnostic products. Integrating Biotest's diagnostic business into Bio-Rad's product portfolio will broaden the company's offering in the area of immunohematology and provide Bio-Rad access to the U.S. markets with a full range of products. Biotest is listed on the SDAX on the Frankfurt Stock Exchange and has more than 2,000 employees worldwide.
"Biotest has an impressive reputation for offering quality products and customer service, and we believe their array of products in the area of immunohematology will fit in well with Bio-Rad's existing diagnostics business," said Norman Schwartz, Bio-Rad President and CEO.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
For more information contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1256614851&article=40031628&symbol=NY%5EBIO
HERCULES, CA -- (Marketwire) -- 10/23/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros. The terms of the agreement were not disclosed at this time. The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.
Based in Germany, Biotest develops, manufactures, and markets pharmaceutical, biotherapeutic, and diagnostic products. Integrating Biotest's diagnostic business into Bio-Rad's product portfolio will broaden the company's offering in the area of immunohematology and provide Bio-Rad access to the U.S. markets with a full range of products. Biotest is listed on the SDAX on the Frankfurt Stock Exchange and has more than 2,000 employees worldwide.
"Biotest has an impressive reputation for offering quality products and customer service, and we believe their array of products in the area of immunohematology will fit in well with Bio-Rad's existing diagnostics business," said Norman Schwartz, Bio-Rad President and CEO.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
For more information contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
http://ih.advfn.com/p.php?pid=nmona&cb=1256614851&article=40031628&symbol=NY%5EBIO
Recent BIO News
- Bio-Rad to Participate in Upcoming Investor Conferences • Business Wire • 05/08/2026 01:00:00 PM
- Bio-Rad Reports First-Quarter 2026 Financial Results • Business Wire • 04/30/2026 08:15:00 PM
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 • Business Wire • 04/16/2026 08:15:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results • Business Wire • 02/12/2026 09:15:00 PM
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 • Business Wire • 01/29/2026 01:30:00 PM
- Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference • Business Wire • 01/06/2026 01:45:00 PM
- Bio-Rad Reports Third-Quarter 2025 Financial Results • Business Wire • 10/29/2025 08:15:00 PM
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 • Business Wire • 10/16/2025 09:30:00 PM
- Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away • Business Wire • 09/30/2025 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:00:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2025 01:00:36 PM
- Bio-Rad's Management to Participate in Upcoming Investor Conferences • Business Wire • 08/25/2025 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2025 09:37:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/05/2025 08:47:16 PM
- Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 • Business Wire • 08/01/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2025 08:17:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2025 08:15:57 PM
- Bio-Rad Reports Second-Quarter 2025 Financial Results • Business Wire • 07/31/2025 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2025 09:20:56 PM
- Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations • Business Wire • 07/28/2025 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2025 08:14:54 PM
